ABSTRACT
Mycobactin biosynthesis in
Mycobacterium tuberculosis
facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5′-
O
-(
N
-salicylsulfamoyl)adenosine] inhibits
M. tuberculosis
growth
in vitro
under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl-AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibited
M. tuberculosis
growth in the mouse lung, providing the first
in vivo
proof of concept for this novel antibacterial strategy.
摘要
结核分枝杆菌中分枝杆菌素的生物合成
结核分枝杆菌
促进铁的获得,而铁是生长和毒力所必需的。分枝菌素生物合成抑制剂水杨酰-AMS [5′-
O
-(
N
水杨酰-AMS[5′- O -(N
结核杆菌
生长
体外
在铁限制条件下抑制结核杆菌的体外生长。在此,我们对小鼠进行了水杨酰-AMS 的单剂量药代动力学研究和单药治疗研究。腹腔注射获得的药代动力学参数值远高于口服给药。5.6 或 16.7 毫克/千克剂量的水杨酰-AMS 单药疗法可显著抑制
结核杆菌
在小鼠肺部的生长,首次在
体内
证明了这种新型抗菌策略的概念。